Clinical Scorecard: FDA approves ravulizumab for IgA nephropathy
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA approves ravulizumab for IgA nephropathy |
| Key Mechanisms | Ravulizumab is a C5 complement inhibitor. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- The FDA granted accelerated approval to ravulizumab-cwvz (Ultomiris) to reduce proteinuria in adults with primary IgAN at risk for disease progression.
- Approval was based on proteinuria reductions in the phase 3 I CAN trial; whether ravulizumab slows kidney function decline has not been established.
- At week 34, UPCR decreased 46.6% from baseline with ravulizumab and 5.6% with placebo; the placebo-adjusted treatment effect was 43.4%.
- Common adverse events with ravulizumab included upper respiratory tract infection, nasopharyngitis, and infusion-related reactions.
- Ravulizumab carries a boxed warning for serious meningococcal infections, including potentially fatal infections.
Guideline-Based Recommendations
Diagnosis
Management
- The FDA-approved indication is reduction of proteinuria in adults with primary IgAN at risk for disease progression.
- The I CAN trial enrolled participants receiving stable standard-of-care treatment for at least 3 months.
- Ravulizumab is administered intravenously using weight-based dosing, with a loading dose followed by maintenance dosing every 8 weeks.
Monitoring & Follow-up
- Complete or update meningococcal vaccination at least 2 weeks before treatment initiation unless delaying therapy poses greater risks.
- Monitor patients for early signs and symptoms of meningococcal infection; susceptibility may persist despite vaccination.
- The ongoing I CAN trial will assess change in eGFR at week 106.
Risks
- Ravulizumab has a boxed warning for serious, potentially fatal meningococcal infections.
- Frequently reported adverse events with ravulizumab included upper respiratory tract infection (11.3%), nasopharyngitis (9.2%), and infusion-related reactions (8.4%).
Patient & Prescribing Data
Adults with primary IgAN at risk for disease progression; the I CAN trial studied participants on stable standard-of-care treatment for at least 3 months.
Intravenous, weight-based dosing begins with a loading dose followed by maintenance doses every 8 weeks. Meningococcal vaccination should be completed or updated at least 2 weeks before initiation unless delaying treatment poses greater risks.
Clinical Best Practices
- Assess meningococcal vaccination status before starting ravulizumab and complete or update vaccination at least 2 weeks before treatment unless delaying therapy poses greater risks.
- Monitor for early signs and symptoms of meningococcal infection even after vaccination.
- Do not interpret proteinuria reduction as established evidence that ravulizumab slows kidney function decline; that outcome remains under evaluation in the ongoing I CAN trial.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
